Connect Biopharma opened higher at $0.70, compared with its previous close of $0.69. In the last trading session, the stock traded between $0.66 and $0.72. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Connect Biopharma is now worth
$ 4.64
Resulting in a loss of
$ 95.36 (95.36%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.02 (-3.18%)
Day High
$0.72
Day Low
$0.66
Day Open
$0.70
Prev Close
$0.69
Volume
1,97,602
1W Return
-14.81%
1M Return
-26.38%
3M Return
-70.14%
6M Return
-71.50%
1Y Return
-56.12%
Fundamentals
Market Cap ($ Mn)
42
PE Ratio
-
PB Ratio
5.23
PEG Ratio
-
ROE
-80.70%
ROCE
-82.85%
EPS (TTM)
-
Investment Returns
1 Week
-14.81%
1 Month
-26.38%
3 Months
-70.14%
6 Months
-71.50%
9 Months
-75.11%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.2
Mar 26
2.8
Jun 26
Updates
2Oct
HC Wainwright reiterates Buy on Connect Biopharma, keeps $7 target
HC Wainwright & Co. reiterated a Buy rating on Connect Biopharma Holdings. Analyst Brandon Folkes maintained the $7 price target. The update reflects no change in the firm's valuation outlook.
1mo ago
1Oct
Connect Biopharma drug cuts COPD treatment failure 81% in Phase 2
Rademikibart reduced treatment failure by 81% versus placebo in Phase 2 COPD trial. New moderate to severe exacerbations fell 85%, with 100% fewer ED visits. Shares rose 25% to $1.24 following positive topline data release. Trial enrolled 159 participants with eosinophil counts ≥300 cells/μL.
Connect Biopharma shares fell 32.46% to $1.16, hitting a 52-week low. Phase 2 asthma trial missed primary statistical significance despite 66% reduction in treatment failure. Key secondary endpoint met: 250 mL increase in lung function vs 120 mL for placebo. Company plans to use lung function as primary endpoint for future Phase 3 trials. Favorable safety profile observed with no new safety signals.
1mo ago
13Aug
Connect Biopharma Q2 Results: Net Loss Widens To $17.3 Million
Connect Biopharma reported a Q2 2026 net loss of $17.3 million, widening from $12.9 million YoY, as R&D costs doubled to $16.3 million for Phase 2 trials. License revenue jumped to $2.8 million from a Simcere milestone. Cash reserves stand at $31.5 million, providing a runway of at least one year.
3mo ago
26Jun
Piper Sandler initiates coverage on Connect Biopharma Hldgs with Overweight rating
Piper Sandler analyst Biren Amin initiated coverage on Connect Biopharma Hldgs with an Overweight rating and announced a price target of $7. The rating suggests a positive outlook for the NASDAQ-listed company, which trades under the ticker CNTB.
4mo ago
25Jun
HC Wainwright reiterates Buy on Connect Biopharma Hldgs
HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Connect Biopharma Hldgs. The firm maintained a price target of $7 for the NASDAQ-listed stock.
